AU2122995A – Inhibition of cataracts and other disorders
– Google Patents
AU2122995A – Inhibition of cataracts and other disorders
– Google Patents
Inhibition of cataracts and other disorders
Info
Publication number
AU2122995A
AU2122995A
AU21229/95A
AU2122995A
AU2122995A
AU 2122995 A
AU2122995 A
AU 2122995A
AU 21229/95 A
AU21229/95 A
AU 21229/95A
AU 2122995 A
AU2122995 A
AU 2122995A
AU 2122995 A
AU2122995 A
AU 2122995A
Authority
AU
Australia
Prior art keywords
cataracts
disorders
inhibition
Prior art date
1994-03-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21229/95A
Inventor
Krystyna Frenkel
Dezider Grunberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University of New York
New York University NYU
Original Assignee
Columbia University of New York
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1994-03-14
Filing date
1995-03-14
Publication date
1995-10-03
1995-03-14
Application filed by Columbia University of New York, New York University NYU
filed
Critical
Columbia University of New York
1995-10-03
Publication of AU2122995A
publication
Critical
patent/AU2122995A/en
Status
Abandoned
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/70—Carbohydrates; Sugars; Derivatives thereof
AU21229/95A
1994-03-14
1995-03-14
Inhibition of cataracts and other disorders
Abandoned
AU2122995A
(en)
Applications Claiming Priority (3)
Application Number
Priority Date
Filing Date
Title
US212569
1994-03-14
US08/212,569
US5591773A
(en)
1994-03-14
1994-03-14
Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
PCT/US1995/003392
WO1995024899A1
(en)
1994-03-14
1995-03-14
Inhibition of cataracts and other disorders
Publications (1)
Publication Number
Publication Date
AU2122995A
true
AU2122995A
(en)
1995-10-03
Family
ID=22791578
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU21229/95A
Abandoned
AU2122995A
(en)
1994-03-14
1995-03-14
Inhibition of cataracts and other disorders
Country Status (3)
Country
Link
US
(2)
US5591773A
(en)
AU
(1)
AU2122995A
(en)
WO
(1)
WO1995024899A1
(en)
Families Citing this family (53)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US5591773A
(en)
1994-03-14
1997-01-07
The Trustees Of Columbia University In The City Of New York
Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
US7655002B2
(en)
1996-03-21
2010-02-02
Second Sight Laser Technologies, Inc.
Lenticular refractive surgery of presbyopia, other refractive errors, and cataract retardation
DE19614740A1
(en)
*
1996-04-15
1997-10-16
Kammann Maschf Werner
Method and device for printing self-supporting individual objects
AU4249497A
(en)
*
1996-09-05
1998-03-26
Research Development Foundation
Inhibition of nuclear transcription factor nf-$g(k)b by caffeic acid phenethyl ester (cape), derivatives of cape, capsaicin (8-methyl-n-vanillyl-6-nonenamide) and resiniferatoxin
KR100231805B1
(en)
*
1997-01-09
1999-12-01
윤재승
Topical formulations containing human epidermal growth factor
US6162393A
(en)
*
1998-08-06
2000-12-19
Ndt, Inc.
Contact lens and ophthalmic solutions
US6379664B1
(en)
1998-09-29
2002-04-30
Board Of Regents University Of Nebraska-Lincoln
Composition and method for the prevention and treatment of oxidative damage in ocular tissues
JP4577751B2
(en)
*
1999-09-02
2010-11-10
塩野義製薬株式会社
Integrase inhibitors containing aromatic heterocyclic derivatives
US7678836B2
(en)
*
1999-11-04
2010-03-16
Fxs Ventures, Llc
Method for rendering a contact lens wettable
SG98409A1
(en)
*
2000-06-21
2003-09-19
Chi Chiang Yang
Pharmaceutical compositions and combinations for the treatment or prophylaxis of disorders related to hiv and retrovirus
JP2002020283A
(en)
*
2000-06-22
2002-01-23
Yang Chi-Chiang
Pharmaceutical composition for treating and preventing disorder associated with hiv and retrovirus, and combination
KR20020005222A
(en)
*
2000-06-28
2002-01-17
치-치앙 양
Pharmaceutical compositions and combinations for the treatment or prophylaxis of disorders related to HIV and retrovirus
US8557868B2
(en)
*
2000-11-04
2013-10-15
Fxs Ventures, Llc
Ophthalmic and contact lens solutions using low molecular weight amines
AU2720602A
(en)
2000-11-08
2002-05-21
Bio Concept Lab
Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US9492582B2
(en)
*
2000-11-08
2016-11-15
Fxs Ventures, Llc
Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
WO2002038077A2
(en)
*
2000-11-08
2002-05-16
Bio-Concept Laboratories
L-histidine in ophthalmic solutions
US20060127496A1
(en)
*
2000-11-08
2006-06-15
Bioconcept Laboratories
L-histidine in ophthalmic solutions
US20070104744A1
(en)
*
2000-11-08
2007-05-10
Fxs Ventures, Llc
Ophthalmic and contact lens solutions containing forms of vitamin b
US9308264B2
(en)
2000-11-08
2016-04-12
Fxs Ventures, Llc
Ophthalmic contact lens solutions containing forms of vitamin B
US20070110782A1
(en)
*
2000-11-08
2007-05-17
Fxs Ventures, Llc
L-histidine in ophthalmic solutions
US20070098813A1
(en)
*
2000-11-08
2007-05-03
Fxs Ventures, Llc
Ophthalmic and contact lens solutions with a peroxide source and a preservative
US6689811B2
(en)
*
2001-04-20
2004-02-10
Wake Forest University
Method of using caffeic acid phenethyl ester and analogs thereof as radiation sensitizers
US20050250752A1
(en)
*
2002-05-09
2005-11-10
Ziawiony Jordan K
Cembranoids with chemopreventive activity
US20040106673A1
(en)
*
2002-09-06
2004-06-03
Conney Allan H.
Compositions and methods for inhibiting proliferation in human prostate cancer cells
KR20040044369A
(en)
*
2002-11-20
2004-05-28
쉬플리 캄파니, 엘.엘.씨.
Multilayer photoresist systems
US7939501B2
(en)
*
2003-04-15
2011-05-10
Smith Francis X
Ophthalmic and contact lens solutions containing peptides as preservative
US7368593B1
(en)
2003-08-18
2008-05-06
Organics L.L.C.
Method of selective esterification
US9889043B2
(en)
2006-01-20
2018-02-13
Lensar, Inc.
System and apparatus for delivering a laser beam to the lens of an eye
US9545338B2
(en)
2006-01-20
2017-01-17
Lensar, Llc.
System and method for improving the accommodative amplitude and increasing the refractive power of the human lens with a laser
US10842675B2
(en)
2006-01-20
2020-11-24
Lensar, Inc.
System and method for treating the structure of the human lens with a laser
US9375349B2
(en)
2006-01-20
2016-06-28
Lensar, Llc
System and method for providing laser shot patterns to the lens of an eye
US8262646B2
(en)
2006-01-20
2012-09-11
Lensar, Inc.
System and method for providing the shaped structural weakening of the human lens with a laser
US20070286925A1
(en)
*
2006-06-08
2007-12-13
The Procter & Gamble Company
Composition for improving eye health
CA2654303C
(en)
*
2006-06-08
2016-07-26
The Iams Company
Use of at least one polyphenol for promoting eye health
US20080167277A1
(en)
*
2006-12-29
2008-07-10
Charles Conrad
Methods of treating skin disorders with caffeic acid analogs
US8500723B2
(en)
2008-07-25
2013-08-06
Lensar, Inc.
Liquid filled index matching device for ophthalmic laser procedures
US8480659B2
(en)
2008-07-25
2013-07-09
Lensar, Inc.
Method and system for removal and replacement of lens material from the lens of an eye
US8450337B2
(en)
*
2008-09-30
2013-05-28
Moleculin, Llc
Methods of treating skin disorders with caffeic acid analogs
EP2456385B1
(en)
2009-07-24
2015-07-22
Lensar, Inc.
System for performing ladar assisted procedures on the lens of an eye
US8758332B2
(en)
2009-07-24
2014-06-24
Lensar, Inc.
Laser system and method for performing and sealing corneal incisions in the eye
US8617146B2
(en)
2009-07-24
2013-12-31
Lensar, Inc.
Laser system and method for correction of induced astigmatism
US8382745B2
(en)
2009-07-24
2013-02-26
Lensar, Inc.
Laser system and method for astigmatic corrections in association with cataract treatment
CN101993372B
(en)
*
2009-08-19
2014-10-22
帕迪有限公司
Method for manufacturing caffeinic phenylester and analogues thereof
WO2011075430A1
(en)
2009-12-14
2011-06-23
University Of Massachusetts
Methods of inhibiting cataracts and presbyopia
US8556425B2
(en)
2010-02-01
2013-10-15
Lensar, Inc.
Purkinjie image-based alignment of suction ring in ophthalmic applications
USD695408S1
(en)
2010-10-15
2013-12-10
Lensar, Inc.
Laser system for treatment of the eye
EP4205633A1
(en)
2010-10-15
2023-07-05
Lensar, Inc.
System and method of scan controlled illumination of structures within an eye
USD694890S1
(en)
2010-10-15
2013-12-03
Lensar, Inc.
Laser system for treatment of the eye
US10463541B2
(en)
2011-03-25
2019-11-05
Lensar, Inc.
System and method for correcting astigmatism using multiple paired arcuate laser generated corneal incisions
US9393154B2
(en)
2011-10-28
2016-07-19
Raymond I Myers
Laser methods for creating an antioxidant sink in the crystalline lens for the maintenance of eye health and physiology and slowing presbyopia development
AU2014236582B2
(en)
2013-03-14
2018-03-29
The University Of Massachusetts
Methods of inhibiting cataracts and presbyopia
EP3373921B1
(en)
2015-11-13
2019-08-28
The University of Massachusetts
Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia
CN110974834A
(en)
*
2019-12-02
2020-04-10
贵州中医药大学
Application of Lonicera fulvidraco acid hydrolysate in pharmacy and preparation method thereof
Family Cites Families (2)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US5008441A
(en)
*
1987-08-04
1991-04-16
The Trustees Of Columbia University In The City Of New York
Caffeic acid esters and methods of producing and using same
US5591773A
(en)
1994-03-14
1997-01-07
The Trustees Of Columbia University In The City Of New York
Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
1994
1994-03-14
US
US08/212,569
patent/US5591773A/en
not_active
Expired – Lifetime
1995
1995-03-14
AU
AU21229/95A
patent/AU2122995A/en
not_active
Abandoned
1995-03-14
US
US08/704,545
patent/US6313165B1/en
not_active
Expired – Fee Related
1995-03-14
WO
PCT/US1995/003392
patent/WO1995024899A1/en
active
Application Filing
Also Published As
Publication number
Publication date
US6313165B1
(en)
2001-11-06
WO1995024899A1
(en)
1995-09-21
US5591773A
(en)
1997-01-07
Similar Documents
Publication
Publication Date
Title
AU2122995A
(en)
1995-10-03
Inhibition of cataracts and other disorders
AU4597596A
(en)
1996-07-03
Prevention of protein aggregation
AU6709596A
(en)
1997-03-19
Amide compounds and use of the same
AU2390695A
(en)
1995-11-29
Placement of endoprostheses and stents
AUPM864894A0
(en)
1994-11-03
Treatment of bowel-dependent neurological disorders
AU4786496A
(en)
1996-08-27
New forms of paroxetin hydrochloride
AU6974996A
(en)
1997-05-15
Compositions for the treatment of dermatological disorders and methods for their use
AU1271297A
(en)
1997-12-09
Inhibitor of ceramidase
AU3075795A
(en)
1996-02-09
Anti-helicobacter acyl derivatives of azolones
AU8154294A
(en)
1995-06-29
Methods of inhibiting atrophy of the skin and vagina
AU3299195A
(en)
1996-04-18
Inhibition of helicobacter
AU7772794A
(en)
1996-05-16
Treatment of obesity
AU1751795A
(en)
1995-09-18
Liposome compositions and methods for the treatment of atherosclerosis
AU2058697A
(en)
1997-09-16
Treatment of sleep disorders
AU4131296A
(en)
1996-05-15
Treatment of disorders with duloxetine
AU1556497A
(en)
1997-08-22
Agents for the treatment and prevention of aids
AU1578295A
(en)
1995-08-29
Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AU8156094A
(en)
1995-06-29
Methods of inhibiting breast disorders
AU1742200A
(en)
2000-06-13
Prevention and treatment of amyloid-associated disorders
AU4248297A
(en)
1998-03-26
Inhibition of viral replication
AU5923998A
(en)
1998-08-25
2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
AU4224096A
(en)
1996-08-08
Use of phenylcyclohexylcarboxamides
AU3118297A
(en)
1997-11-26
Sok-1 and methods of use
AU2060295A
(en)
1995-08-29
Inhibitors of cell-mediated disorders
AU4505996A
(en)
1996-06-26
7-vinylidene cephalosporins and methods of using the same
None